Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) will report fourth quarter results on February 24, 2026 at 4:00 PM ET, followed by a management conference call at 4:30 PM ET.
According to the company, the call will be webcast and accessible via the Investors & Media section of Cytokinetics' website, with an archived replay available for six months.
Positive
- None.
Negative
- None.
News Market Reaction – CYTK
On the day this news was published, CYTK gained 1.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CYTK gained 3.01% while close peers showed mixed moves: AXSM, LEGN, ABVX, and NUVL were modestly positive, and RYTM declined 5.2%, suggesting stock-specific strength rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Patient grants | Positive | +1.6% | Grants to HCM advocacy groups to expand education and engagement initiatives. |
| Jan 27 | Awareness campaign | Positive | +1.3% | Launch of On Track with HCM program featuring Olympic athlete partnership. |
| Jan 27 | Drug availability | Positive | +1.3% | MYQORZO (aficamten) made available in U.S. following prior FDA approval. |
| Jan 20 | Inducement awards | Neutral | -1.2% | Equity inducement grants and RSUs issued to new employees under listing rules. |
| Jan 05 | Conference presentation | Positive | +5.5% | Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
Recent company news, including drug availability and awareness initiatives, has often coincided with positive one-day price reactions, while routine equity/compensation items saw weaker or negative responses.
Over the past weeks, CYTK’s news flow centered on commercial rollout and visibility for MYQORZO and hypertrophic cardiomyopathy (HCM) awareness. On Jan 27, 2026, availability of MYQORZO in the U.S. and an HCM awareness campaign each saw shares rise about 1.3%. A J.P. Morgan conference presentation on Jan 12, 2026 preceded a 5.45% gain. In contrast, inducement equity grants on Jan 15, 2026 were followed by a 1.16% decline. The current earnings-date notice fits a pattern of scheduled, communication-focused updates.
Market Pulse Summary
This announcement schedules Cytokinetics’ Q4 2025 earnings release for February 24, 2026, with results at 4:00 PM ET and a conference call at 4:30 PM ET. It follows a series of communications-focused updates, including MYQORZO availability and HCM awareness initiatives. Ahead of results, the stock trades above its 200-day MA of $49.34 and within 5.89% of its $70.98 52-week high, underscoring the importance of forthcoming financial and business updates.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics’ website for six months.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the U.S. Food and Drug Administration and the China National Medical Products Administration. The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in first quarter in 2026. Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZOTM is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When will Cytokinetics (CYTK) release its Q4 2025 earnings?
How can investors join the Cytokinetics (CYTK) Q4 2025 earnings call on February 24, 2026?
Will Cytokinetics (CYTK) provide a replay of the February 24, 2026 earnings webcast?
What time is the Cytokinetics (CYTK) management Q&A for Q4 2025?
Where is the Cytokinetics (CYTK) Q4 2025 earnings webcast hosted online?
Will Cytokinetics (CYTK) include business updates in its February 24, 2026 earnings call?
